Cabazitaxel
Cabazitaxel is a semi-synthetic taxoid that is an effective antineplastic agent used in the treatment of prostate cancer and breast cancer. Cabazitaxel is shown to disrupt the microtubular network in cells that exhibit P-glycoprotein (Pgp) mediated drug resistance. Its poor affinity for Pgp makes it a more effective therapeutic agent than docetaxel in cancer cells that become resistant to taxane class of cancer drugs.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18846050
| Cas No. |
183133-96-2 |
|---|---|
| Purity |
≥98% |
| Formula |
C45H57NO14 |
| Formula Wt. |
835.94 |
| Chemical Name |
1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate) |
| IUPAC Name |
(2α,5β,7β,10β,13α)-4-Acetoxy-1-hydroxy-13-{[(2R,3S)-2-hydroxy-3-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-3-phenylpropanoyl]oxy}-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate |
| Synonym |
XPR-6258; TXD 258; Taxoid XRP6258; RPR 116258A, jevtana. |
| Solubility |
Soluble in DMSO (~100 mg/mL), ethanol (~50 mg/mL). Sparingly soluble in water. |
